Pfizer: ACIP votes to expand recommendation for Pfizer's RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease

Pfizer Inc. announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory